Evidence map›Paper›PMID 39256164›Full record

ArticleJournal of neuroendocrinology2024

Lack of a genetic risk continuum between pubertal timing in the general population and idiopathic hypogonadotropic hypogonadism.

Lacey Plummer, Ravikumar Balasubramanian, Maria Stamou, Mark Campbell, Pranav Dewan, Nora Bryant, Kathryn Salnikov, Margaret Lippincott, Stephanie Seminara

Abstract read
In one paragraph

Article in Journal of neuroendocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Reversal of Congenital Hypogonadotropic Hypogonadism.The Journal of clinical endocrinology and metabolism · 2026
    Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lacey PlummerCenter for Reproductive Medicine, Reproductive Endocrine Unit and The Endocrine Unit of the Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Ravikumar BalasubramanianCenter for Reproductive Medicine, Reproductive Endocrine Unit and The Endocrine Unit of the Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0001-6008-5585
Maria StamouCenter for Reproductive Medicine, Reproductive Endocrine Unit and The Endocrine Unit of the Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Mark CampbellCenter for Reproductive Medicine, Reproductive Endocrine Unit and The Endocrine Unit of the Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Pranav DewanCenter for Reproductive Medicine, Reproductive Endocrine Unit and The Endocrine Unit of the Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Nora BryantCenter for Reproductive Medicine, Reproductive Endocrine Unit and The Endocrine Unit of the Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Kathryn SalnikovCenter for Reproductive Medicine, Reproductive Endocrine Unit and The Endocrine Unit of the Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Margaret LippincottCenter for Reproductive Medicine, Reproductive Endocrine Unit and The Endocrine Unit of the Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Stephanie SeminaraCenter for Reproductive Medicine, Reproductive Endocrine Unit and The Endocrine Unit of the Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

Funding

The Massachusetts General Hospital Harvard Center for Reproductive MedicineP50HD104224 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI TALKOWSKI, MICHAEL E · 2021 to 2025
$7.8M
Towards Curative Therapies for Hypogonadotropic DiseasesR37HD043341 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI Stephanie Beth Seminara · 2020 to 2026
$5.8M
Dissection of the Molecular Basis of Pleiotropy Between GnRH Neuronal Development and Cranial Suture FusionR01DE031452 · NIDCR · MASSACHUSETTS GENERAL HOSPITAL · PI Erica Ellen Davis, Stephanie Beth Seminara · 2022 to 2026
$3.9M
Integrative Approaches to Decipher Genetic Determinants of Disease Penetrance in Prokineticin 2 Pathway Related Human Reproductive DisordersR01HD096324 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI BALASUBRAMANIAN, RAVIKUMAR · 2018 to 2022
$1.7M
Kisspeptin: A Novel Regulator of Insulin in PregnancyK23HD097296 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI LIPPINCOTT, MARGARET FLYNN · 2019 to 2023
$864k
Deciphering the Role of Copy Number Variants in Neuroendocrine Disorders of InfertilityF32HD108873 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI STAMOU, MARIA · 2022 to 2024
$233k
FDA HHS R01 FD007843National Institute of Child Health and Human Development F32HD108873National Institute of Child Health and Human Development K23HD097296National Institute of Child Health and Human Development P50HD104224National Institute of Child Health and Human Development R01HD096324National Institute of Child Health and Human Development R37HD043341NICHD NIH HHS F32 HD108873NICHD NIH HHS K23 HD097296NICHD NIH HHS P50 HD104224NICHD NIH HHS R01 HD096324NICHD NIH HHS R37 HD043341NIDCR NIH HHS R01 DE031452NIDCR NIH HHS R01DE031452
6 · The paper itself

Abstract

Pubertal timing is a highly heritable trait in the general population. Recently, a large-scale exome-wide association study has implicated rare variants in six genes (KDM4C, MC3R, MKRN3, PDE10A, TACR3, and ZNF483) as genetic determinants of pubertal timing within the general population. Two of the genes (TACR3, MKRN3) are already implicated in extreme disorders of pubertal timing. This observation suggests that there may be a pervasive "genetic risk continuum" wherein genes that govern pubertal timing in the general population, by extension, may also be causal for rare Mendelian disorders of pubertal timing. Hence, we hypothesized that the four novel genes linked to pubertal timing in the population will also contribute to idiopathic hypogonadotropic hypogonadism (IHH), a genetic disorder characterized by absent puberty. Exome sequencing data from 1322 unrelated IHH probands were reviewed for rare sequence variants (RSVs) (minor allele frequency bins: <1%; <0.1%; <0.01%) in the six genes linked to puberty in the general population. A gene-based rare variant association testing (RVAT) was performed between the IHH cohort and a reference public genomic sequences repository-the Genome Aggregation Database (gnomAD). As expected, RVAT analysis showed that RSVs in TACR3, a known IHH gene, were significantly enriched in the IHH cohort compared to gnomAD cohort across all three MAF bins. However, RVAT analysis of the remaining five genes failed to show any RSV enrichment in the IHH cohort across all MAF bins. Our findings argue strongly against a pervasive genetic risk continuum between pubertal timing in the general population and extreme pubertal phenotypes. The biologic basis of such distinct genetic architectures' merits further evaluation.

Indexed as

HypogonadismPubertyAdolescentFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansMaleReceptors, Neurokinin-3Ubiquitin-Protein LigasesYoung AdultMKRN3 protein, humanReceptors, Neurokinin-3TACR3 protein, humanUbiquitin-Protein Ligasesdelayed pubertygeneticsidiopathic hypogonadotropic hypogonadismpuberty

Identifiers

PMID39256164
PMCPMC11444870

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.